News

Journal criticises Vioxx study for omitting three heart attacks

BMJ 2005; 331 doi: 10.1136/bmj.331.7530.1423 (Published 15 December 2005)
Cite this as: BMJ 2005;331:1423.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    The New England Journal of Medicine has issued an editorial “statement of concern” about the omission of data in a paper it published. It said that three heart attacks were omitted from a study comparing rofecoxib (Vioxx) with naproxen, under-stating the risks of rofecoxib.

    The editorial by the journal's three top editors will appear in print in the 29 December issue but was published online on 8 December (www.nejm.org, doi: 10.1056/NEJMe058314).

    It said: “Relevant data on cardiovascular outcomes had been deleted from the VIGOR [Vioxx gastrointestinal outcomes research] manuscript prior to its submission to the journal and… the authors had withheld data on other relevant cardiovascular outcomes. …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular